CO2021015698A2 - Moduladores de thr-β y métodos de uso de estos - Google Patents

Moduladores de thr-β y métodos de uso de estos

Info

Publication number
CO2021015698A2
CO2021015698A2 CONC2021/0015698A CO2021015698A CO2021015698A2 CO 2021015698 A2 CO2021015698 A2 CO 2021015698A2 CO 2021015698 A CO2021015698 A CO 2021015698A CO 2021015698 A2 CO2021015698 A2 CO 2021015698A2
Authority
CO
Colombia
Prior art keywords
formula
methods
thr
modulators
iiid
Prior art date
Application number
CONC2021/0015698A
Other languages
English (en)
Inventor
Koen Vandyck
Pierre Jean-Marie Bernard Raboisson
David Mcgowan
Jerome Deval
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of CO2021015698A2 publication Critical patent/CO2021015698A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

En la presente se divulgan compuestos de la Fórmula I: (I) TL-La-CE-HD o una sal, profármaco, amida o éster aceptable desde el punto de vista farmacéutico de estos, donde i) TL es una porción de la Fórmula IIa, IIb, IIIa, IIIb, IIIc o IIId; ii) CE es una porción de la Fórmula IV; iii) HD es una porción de la Fórmula V o VI; donde los sustituyentes son como se definen en la presente. También se divulgan composiciones farmacéuticas que comprenden los compuestos anteriores y métodos para tratar enfermedades mediante la administración o el contacto de un paciente con uno o más de los compuestos anteriores. (IIa) (IIb) (IIIa) (IIIb) (IIIc) (IIId)
CONC2021/0015698A 2019-05-08 2021-11-23 Moduladores de thr-β y métodos de uso de estos CO2021015698A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962845252P 2019-05-08 2019-05-08
US201962944052P 2019-12-05 2019-12-05
US202063005661P 2020-04-06 2020-04-06
PCT/US2020/031904 WO2020227549A1 (en) 2019-05-08 2020-05-07 MODULATORS OF THR-β AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
CO2021015698A2 true CO2021015698A2 (es) 2022-01-17

Family

ID=70919081

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015698A CO2021015698A2 (es) 2019-05-08 2021-11-23 Moduladores de thr-β y métodos de uso de estos

Country Status (17)

Country Link
US (2) US11091467B2 (es)
EP (1) EP3965884A1 (es)
JP (1) JP2022532706A (es)
KR (1) KR20220017917A (es)
CN (1) CN114096531A (es)
AU (1) AU2020267576A1 (es)
BR (1) BR112021021718A2 (es)
CA (1) CA3139101A1 (es)
CL (1) CL2021002883A1 (es)
CO (1) CO2021015698A2 (es)
IL (1) IL287720A (es)
MA (1) MA55890A (es)
MX (1) MX2021013472A (es)
PE (1) PE20220255A1 (es)
SG (1) SG11202111552YA (es)
TW (1) TW202108569A (es)
WO (1) WO2020227549A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020227549A1 (en) * 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CA3158379A1 (en) * 2019-11-26 2021-06-03 Hejun Lv 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof
WO2021129465A1 (zh) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
WO2022053028A1 (zh) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用
JP2023541870A (ja) * 2020-09-10 2023-10-04 ▲蘇▼州科睿思制▲葯▼有限公司 レスメチロム（ｒｅｓｍｅｔｉｒｏｍ）の結晶形態、その調製方法、及びその使用について
AU2021376281A1 (en) * 2020-11-06 2023-06-15 Aligos Therapeutics, Inc. Pyridazinone derivatives as thyroid receptor agonists and uses thereof
JP2023548541A (ja) * 2020-11-06 2023-11-17 アリゴス セラピューティクス，インコーポレーテッド オキシインドール及びその使用方法
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
AU2022228569A1 (en) * 2021-03-03 2023-10-12 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
CN117279911A (zh) * 2021-05-21 2023-12-22 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
WO2023023474A1 (en) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
AU2022339846A1 (en) 2021-09-01 2024-03-14 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
WO2023039076A1 (en) 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
DK1088819T3 (da) 1999-09-30 2005-09-12 Pfizer Prod Inc 6-azauracilderivater som thyroidreceptorligander
DK1262177T3 (da) 2001-05-31 2006-11-20 Pfizer Prod Inc Medicinsk brug af thyromimetiske forbindelser til behandling af hårtab og kompositioner
JPWO2003064369A1 (ja) * 2002-01-30 2005-05-26 キッセイ薬品工業株式会社 新規な甲状腺ホルモン受容体リガンド、それを含有する医薬組成物、およびそれらの用途
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
WO2004047827A1 (en) 2002-11-25 2004-06-10 Pfizer Products Inc. Method for promoting nail growth using thyromimetic compounds
CA2614529C (en) * 2005-07-21 2011-06-28 F. Hoffmann-La Roche Ag Pyridazinone derivatives as thyroid hormone receptor agonists
MX2008008337A (es) * 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
EP2036887A1 (en) * 2006-06-28 2009-03-18 Sanwa Kagaku Kenkyusho Co., Ltd Novel 6-5 bicycic heterocyclic derivative and medical use thereof
WO2008104752A1 (en) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
CN102459185B (zh) * 2009-04-20 2015-06-03 田边三菱制药株式会社 新型甲状腺激素β受体激动剂
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
PL2695611T3 (pl) 2012-08-06 2015-03-31 Dr August Wolff Gmbh & Co Kg Arzneimittel Eprotirom do stosowania w profilaktyce i/lub leczeniu zaburzeń włosów oraz jego kompozycje
DK3689853T3 (da) 2012-09-17 2022-03-07 Madrigal Pharmaceuticals Inc Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf
CN105517574B (zh) 2013-07-09 2019-01-18 百时美施贵宝公司 丙型肝炎病毒抑制剂的组合产品
US10303567B2 (en) 2013-08-15 2019-05-28 Entit Software Llc Managing database nodes
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
CA2972919A1 (en) 2015-01-09 2016-07-14 Gilead Apollo, Llc Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
US10682344B2 (en) 2016-06-03 2020-06-16 Chemocentryx, Inc. Method of treating liver fibrosis
ES2924257T3 (es) 2016-10-18 2022-10-05 Madrigal Pharmaceuticals Inc Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta
BR112019018162A2 (pt) 2017-03-13 2020-04-07 Genfit Composições farmacêuticas para terapia de combinação
MX2019012534A (es) 2017-04-18 2020-08-17 Genfit Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico.
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
JP7273022B2 (ja) 2017-07-19 2023-05-12 バイオ―ラッド ヨーロッパ ゲーエムベーハー 非アルコール性脂肪性肝炎及び肝線維症ステータスを同時に評価するバイオマーカの組み合わせ
WO2019099457A1 (en) 2017-11-14 2019-05-23 Quixgen, Inc. Benzodioxinone compounds
CA3084728A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN111646979B (zh) 2018-01-23 2021-08-31 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
WO2019178023A1 (en) 2018-03-12 2019-09-19 Yale University Methods of Treating or Preventing Acute Respiratory Distress Syndrome
EP3787618A4 (en) 2018-05-04 2022-05-04 Cirius Therapeutics, Inc. THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES
CN108727344A (zh) 2018-05-14 2018-11-02 嘉兴特科罗生物科技有限公司 一种化合物及其合成方法和应用
US11964964B2 (en) 2018-06-12 2024-04-23 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
WO2019239436A1 (en) 2018-06-14 2019-12-19 Alma Mater Studiorum - Universita' Di Bologna Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug
CN110627773B (zh) 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
TW202019914A (zh) 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
US10800767B2 (en) 2018-08-24 2020-10-13 Terns, Inc. Thyroid hormone receptor beta agonist compounds
WO2020077123A1 (en) 2018-10-12 2020-04-16 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US20210355110A1 (en) * 2018-10-12 2021-11-18 InventisBio Co., Ltd. Thyroid hormone receptor agonists
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020169069A1 (en) 2019-02-21 2020-08-27 Nanjing Ruijie Pharma Co., Ltd. Novel compounds and their uses as thyroid hormone receptor agonists
WO2020227549A1 (en) * 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
TW202108556A (zh) 2019-05-10 2021-03-01 大陸商深圳微芯生物科技股份有限公司 一種噠嗪酮衍生物及其應用
IT201900006923A1 (it) 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
TW202115029A (zh) 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途
GB2603330B (en) 2019-08-19 2023-08-09 Hepagene Therapeutics Hk Ltd Heterocyclic THR-B receptor agonist compound and preparation method and use therefor
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
WO2021041237A1 (en) 2019-08-23 2021-03-04 Terns, Inc. Thyroid hormone receptor beta agonist compounds
WO2021043185A1 (en) 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. A compound as a thyroid hormone beta receptor agonist and use thereof
US20220356177A1 (en) 2019-09-12 2022-11-10 Terns, Inc. Thyroid hormone receptor beta agonist compounds
EP4036090A4 (en) 2019-09-24 2023-11-15 Sunshine Lake Pharma Co., Ltd. CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF

Also Published As

Publication number Publication date
SG11202111552YA (en) 2021-11-29
PE20220255A1 (es) 2022-02-16
CL2021002883A1 (es) 2022-10-28
WO2020227549A8 (en) 2021-05-27
EP3965884A1 (en) 2022-03-16
IL287720A (en) 2021-12-01
US11091467B2 (en) 2021-08-17
US20210355112A1 (en) 2021-11-18
MX2021013472A (es) 2022-01-06
TW202108569A (zh) 2021-03-01
CA3139101A1 (en) 2020-11-12
US20200354345A1 (en) 2020-11-12
BR112021021718A2 (pt) 2022-01-18
KR20220017917A (ko) 2022-02-14
MA55890A (fr) 2022-03-16
CN114096531A (zh) 2022-02-25
JP2022532706A (ja) 2022-07-19
AU2020267576A1 (en) 2021-12-09
WO2020227549A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
PE20221910A1 (es) Derivados de pirazolilo utiles como agentes anticancerigenos
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
AR116604A1 (es) Inhibidores de kras g12c
DOP2022000117A (es) Inhibidores de kras g12c
PE20210176A1 (es) Inhibidores de arginasa y sus metodos de uso
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
UY39261A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2021014210A2 (es) Compuestos de pirrol
CO2022015157A2 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR119857A1 (es) Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
ECSP23089582A (es) Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio
CO2021017202A2 (es) Compuestos tricíclicos
CO2021011039A2 (es) Inhibidores de arginasa y métodos de uso de estos
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
AR116080A1 (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona